Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P13995
UPID:
MTDC_HUMAN
Alternative names:
-
Alternative UPACC:
P13995; Q53G90; Q53GV5; Q53S36; Q7Z650
Background:
The Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial, identified by the accession number P13995, plays a crucial role in cellular metabolism. Its unique ability to utilize NAD-specific dehydrogenase activity, albeit with reduced efficiency for NADP, highlights its versatility in enzymatic functions.
Therapeutic significance:
Understanding the role of Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial could open doors to potential therapeutic strategies. Its pivotal role in metabolic pathways underscores its potential as a target for therapeutic intervention.